On 18 September 2024, NMIN spin-off company NanoVation Therapeutics (NTx) announced …
April 2019 – July 2024
NMIN completed its NCE mandate in July 2024 and is no longer active.
NMIN News
L to R: Company co-founders Dr. Logan Zettle, Dr. Chirag M. …
On 9 October 2024, NMIN spin-off company SeraGene Therapeutics was awarded …
The NanoMedicines Innovation Network (NMIN) is pleased to announce 36 new …
The NanoMedicines Innovation Network (NMIN) is pleased to announce the 8 …
On 6 May 2024, the Government of Canada announced Stage 2 …
In July 2023, NMIN researcher Dr. Gang Zheng co-founded the new …
Photo: Michael Valic pitching (inset) and holding the first-place prize cheque …
In a formal ceremony that took place in downtown Vancouver, BC, …
A selection of workshop participants (L to R): Miguel Tsai (NanoVation …
The NanoMedicines Innovation Network (NMIN) is pleased to announce the 14 …
NMIN announces the completion of the first NMIN ResearchSNIPS: a clear-language …
NMIN Board Chair Inès Holzbaur kicks off the conference From January …
NMIN’s Founding Scientific Director Dr. Pieter Cullis delivers his keynote presentation …
L to R: NMIN Executive Director Dr. Diana Royce; HQP Logan …
Dr. Pieter Cullis, NMIN’s Founding Scientific Director, has been named as …
NMIN
about
From 2019 to 2024: Advancing research, innovation and training in nanomedicines to maintain Canada as the world leader in the field.
The NanoMedicines Innovation Network (NMIN) was funded from April 2019 to July 2024 by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.
NMIN advanced “smart” medicines to cure disease by delivering small molecule drugs more specifically to disease sites and enabling the clinical use of gene therapies.
NMIN brought Principal Investigators from institutions across Canada together with companies and not-for-profit research and granting institutions in a network committed to expanding and improving Canada’s position as a global leader in nanomedicines R&D.
NMIN
focus
Developing nanomedicines
that enhance the therapeutic properties of small molecule drugs, and enable gene therapies.
Developing diagnostics
that enable more precise disease detection and treatment, based on nanotechnology.
Training new scientists
in the technology & business of nanomedicines, guided by skills required by the R&D community.
Translating nanomedicine
products and technologies, by implementing a cohesive IP and commercialization strategy.
NMIN
Former Management Team
Gilbert Walker
Scientific Director & CEO (2022-2024)
Associate Scientific Director (2019-2022)
Diana Royce
Executive Director
(2019-2024)
xx
Pieter Cullis
Founding Scientific Director & CEO (2019-2021)
Christine Allen
Scientific Director & CEO (2021-2022)
NMIN
Contact
NMIN
2350 Health Sciences Mall, Room 5451 | University of British Columbia | Vancouver, BC V6T 1Z3 Canada
NMIN
2350 Health Sciences Mall, Room 5451 | University of British Columbia | Vancouver, BC V6T 1Z3 Canada
info@nanomedicines.ca